BCM
ANTX icon

Bronte Capital Management’s AN2 Therapeutics ANTX Stock Holding History

Bronte Capital Management’s Portfolio ANTX Stock Details ANTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$52.7K Buy
+10,895
New +$46.9K 0.01% 44

Other funds holding ANTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return

Bronte Capital Management's ANTX Position: Q2 2026 in Review

Bronte Capital Management opened a new position in AN2 Therapeutics (ANTX) in Q2 2026: 10,895 shares worth $52.7K. The stake represents 0.01% of the portfolio and ranks #44 among its holdings.

17 funds tracked by Wall St. Rank hold ANTX as of Q2 2026.

  • Bronte Capital Management held 10,895 shares of AN2 Therapeutics worth $52.7K as of Q2 2026.
  • AN2 Therapeutics was a new Bronte Capital Management position in Q2 2026.
  • AN2 Therapeutics made up 0.01% of Bronte Capital Management's portfolio in Q2 2026, its #44 holding.
  • 17 funds tracked by Wall St. Rank held AN2 Therapeutics as of Q2 2026.

Based on Bronte Capital Management's 13F filing for Q2 2026, filed 5 Aug 2026.